Abbott Laboratories $ABT Stake Lessened by Twin Capital Management Inc.

Twin Capital Management Inc. trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 28.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,176 shares of the healthcare product maker’s stock after selling 15,997 shares during the period. Abbott Laboratories makes up about 0.7% of Twin Capital Management Inc.’s holdings, making the stock its 22nd biggest position. Twin Capital Management Inc.’s holdings in Abbott Laboratories were worth $5,515,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. Clear Creek Financial Management LLC grew its holdings in shares of Abbott Laboratories by 10.9% during the 2nd quarter. Clear Creek Financial Management LLC now owns 5,009 shares of the healthcare product maker’s stock valued at $681,000 after acquiring an additional 494 shares in the last quarter. Mainstay Capital Management LLC ADV acquired a new position in shares of Abbott Laboratories in the second quarter worth $222,000. Finally, Callan Family Office LLC raised its holdings in shares of Abbott Laboratories by 67.8% during the second quarter. Callan Family Office LLC now owns 98,163 shares of the healthcare product maker’s stock worth $13,351,000 after acquiring an additional 39,649 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Oppenheimer cut their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Leerink Partners decreased their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Raymond James Financial cut their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Jefferies Financial Group upped their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $110.86 on Friday. The firm has a market capitalization of $192.77 billion, a PE ratio of 29.80, a PEG ratio of 1.74 and a beta of 0.75. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm’s fifty day simple moving average is $120.86 and its 200 day simple moving average is $126.89.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.